Graft-vs-Host Disease (GVHD)

Latest News

October 18th 2024

A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff

By Laura Joszt, MA

March 25th 2024

Amid Search for Biomarkers in oGVHD, Research Focuses on Cytokine Profile of Tears

By AJMC Contributor

March 15th 2024

For Chronic GVHD, Second-Line Therapies Vary Widely

By Jared Kaltwasser

March 12th 2024

Review Highlights Role of JAK Inhibition in Advancement of GVHD Prevention, Treatment

By AJMC Contributor

March 8th 2024

GVHD Treatment Response at Day 14 as Effective as 28-Day Model, Say Researchers

By AJMC Contributor

ASH 2024 Post Conference Perspectives: Chronic Graft-vs-Host Disease Management

Learn about emerging therapies such as axatilimab, and ibrutinib and rituximab combinations, and how they’re reshaping the treatment landscape for chronic graft-vs-host disease.

Watch Now

Sergio A. Giralt, MD, discusses how the approval of axatilimab and emerging therapies, including ibrutinib and rituximab combinations, are reshaping the treatment landscape for chronic graft-vs-host disease (cGVHD).

More News

Patient speaking with doctor | Image credit: DragonImages - adobe.stock.com

March 1st 2024

PROs May Successfully Risk Stratify Patients With Cutaneous Chronic GVHD

Laura Joszt, MA

Two existing, well-validated patient-reported outcome (PRO) measures may be useful as a prognostic marker for mortality and assist with treatment selection for patients with cutaneous chronic graft-vs-host disease (GVHD).

January 6th 2024

Understanding AGAVE-201 and Unmet Need in Chronic GVHD

Produced by Mary Caffrey

July 30th 2022

GVHD May Mimic Eosinophilic GI Disorders Following Bone Marrow Transplant

Rose McNulty

After years of dependence on systemic corticosteroids, ruxolitinib treatment was effective for an adolescent patient with graft-versus-host disease (GVHD) who was initially thought to have eosinophilic gastroenteritis.